Use of infliximab in particular clinical settings: Management based on current evidence

American Journal of Gastroenterology

Volumn 104, Issue 6, 2009, Pages 1575-1586

  Papa, Alfredo ^a,b   Mocci, Giammarco ^a   Bonizzi, Michele ^a   Felice, Carla ^a   Andrisani, Gianluca ^a   De Vitis, Italo ^a   Guidi, Luisa ^a   Gasbarrini, Antonio ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ADALIMUMAB; ADEFOVIR DIPIVOXIL; ANTIVIRUS AGENT; AZATHIOPRINE; ENTECAVIR; ETANERCEPT; INFLIXIMAB; LAMIVUDINE; MERCAPTOPURINE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; WART VIRUS VACCINE;

CLINICAL PRACTICE; CLINICAL TRIAL; CROHN DISEASE; DRUG USE; ENTERITIS; HEPATITIS B; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY CARCINOMA; LYMPHOMA; NONHUMAN; PANCREAS CANCER; PREGNANCY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; T CELL LYMPHOMA; TREATMENT OUTCOME; TUBERCULOSIS; ULCERATIVE COLITIS; VIRUS INFECTION;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; COLITIS, ULCERATIVE; CROHN DISEASE; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); PRACTICE GUIDELINES AS TOPIC;

EID: 66949179344     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2009.162     Document Type: Review

References (124)

1. Hommes DW, Oldenburg B, Van Bodegraven AA et al. Guidelines for treatment with infliximab for Crohn's disease. Neth J Med 2006;64:219-29.
2. Koike R, Takeuchi T, Eguchi K et al. Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis. Mod Rheumatol 2007;17:451-8.
3. Fautrel B, Pham T, Mouterde G et al. Recommendations of the French Society for Rheumatology regarding TNF-α antagonist therapy in patients with rheumatoid arthritis. Joint Bone Spine 2007;74:627-37.
4. Ledingham J, Deighton C. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology 2005;44:157-63.
5. Sandborn WJ, Hanauer SB. Infiximab in the treatment of Crohn's disease: a user's guide for clinicians. Am J Gastr 2002;97:2962-72.
6. Viget N, Vernier-Massouille G, Salmon-Ceron D et al. Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis. Gut 2008;57:549-58.
7. Kunst H. Diagnosis of latent TB infection: the potential role of new technologies. Resp Med 2006;100:2098-106.
8. World Health Organisation Rockville Fact Sheet no. 104: TB (accessed on 23 June 2008) http://www.who.int/mediacentre/factsheets/fs104/en/index.html, 2006.
9. Fauci AS, Touchette NA, Folkers GK. Emerging infectious diseases: a 10-year perspective from the National Institute of Allergy and Infectious Diseases. Emerg Infect Dis 2005;11:519-25 (serial on the internet) (accessed on 23 June 2008) http://www.cdc.gov/ncidod/EID/vol11no04/04-1167.htm.
10. Dye C, Scheele S, Dolin P et al. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 1999;282:677-86.
11. National Institute for Health and Clinical Excellence. Tuberculosis: Clinical Diagnosis and Management of Tuberculosis, and Measures for its Prevention and Control , Clinical Guideline 33 National Institute for Clinical Excellence: London , 2006.
12. Flynn JL, Goldstein MM, Chan J et al. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 1995;2:561-72.
13. Turner J, Frank AA, Brooks JV et al. Pentoxifylline treatment of mice with chronic pulmonary tuberculosis accelerates the development of destructive pathology. Immunology 2001;102:248-53.
14. Senaldi G, Yin S. Corynebacterium parvum- and Mycobacterium bovis bacillus Calmette-Guerin induced granuloma formation is inhibited in TNF receptor I (TNF-RI) knockout mice and by treatment with soluble TNF-RI. J Immunol 1996;157:5022-6.
15. Kindler V, Sappino AP, Grau GE et al. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 1989;56:731-40.
16. Mohan VP, Scanga CA, Yu K et al. Efects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. Infect Immun 2001;69:1847-55.
17. Keane J, Gershon S, Wise RP et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104.
18. Raval A, Akhavan-Toyerskani G, Brinker A et al. Characteristics of spontaneous cases of tuberculosis associated with infliximab. Ann Intern Med 2007;114:699-702.
19. Rieder HL, Snider Jr DE, Cauthen GM. Extrapulmonary tuberculosis in the United States. Am Rev Respir Dis 1990141:347-51.
20. Colombel JF, Lofus EV, Tremaine WJ et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004;126:19-31.
21. Fidder H, Schnitzler F, Ferrante M et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single center cohort study. Gut 2008 (18 November 2008; e-pub ahead of print).
22. Lichtenstein GR, Feagan BG, Cohen RD et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006;4:621-30.
23. Lichtenstein GR, Cohen RD, Feagan BG et al. Safety of Infiximab and other Crohn's disease therapies: Treat ™ Registry Data with 24,575 patient-years of follow-up. Am J Gastroentol 2008;103 (Suppl 1):S436.
24. Periodic Safety Update Report (PSUR) 16: Infliximab; p. 69, Table 21. October 2007.
25. Periodic Safety Update Report (PSUR) 18: Infliximab; pp. 16- 17. October 2008.
26. Periodic Safety Update Report (PSUR) 18: Infliximab; p. 140. October 2008.
27. Theis VS, Rhodes JM. Review article: minimizing tuberculosis during anti-tumor necrosis factor-alpha treatment in inflammatory bowel disease. Aliment Pharm Therap 2008;27:19-30.
28. Mariette X, Salmon D. French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers. Ann Rheum Dis 2003;62:791.
29. Furst DE Cush J, Kaufmann S et al. Preliminary guidelines for diagnosing and treating tuberculosis in patients with rheumatoid arthritis in immunosuppressive trials or being treated with biologic agents. Ann Rheum Dis 2002;61(suppl. 2):ii62-3.
30. American Thoracic Society. Targeted tuberculin testing and treatment of latent TB infection. ATS guidelines. http://www.thoracic.org/sections/ publications/statements/pages/mtpi/latentTB1-27.html, 1999.
31. British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing MTB infection and disease in patients due to start anti-TNF alpha treatment. Thorax 2005;60:800-5.
32. Rampton DS. Preventing TB in patients with Crohn's disease needing infliximab or other anti-TNF therapy. Gut 2005;54:1360-2.
33. Mow WS, Abreu-Martin MT, Papadakis KA et al. High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. Clin Gastroenterol Hepatol 2004;2:309-13.
34. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 2008;149:1-9.
35. Oxford Immunotec. http://wwwoxfordimmunoteccom//, 2007.
36. Efhimiou P, Sood S. Quantiferon TB gold test: the new standard for screening of latent TB in patients with rheumatoid arthritis. Ann Rheum Dis 2007;66:276.
37. Ravn P, Munk ME, Andersen AB et al. Reactivation of TB during immunosuppressive treatment in a patient with a positive Quantiferon-RD1 test. Scand J Infect Dis 2004;36:499-501.
38. Matulis G, Jüni P, Villiger PM et al. Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases. Performance of Mycobacterium tuberculosis antigen-specific interferon gamma assays. Ann Rheum Dis 2008;67:84-90.
39. Schoepfer AM, Flogerzi B, Falleger S et al. Comparison of interferon-gamma relase assay versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease. Am J Gastroenterol 2008;103:1-8.
40. Hornum MG, Mortensen KL, Kamper AL et al. Limitations of the Quan-tiFeron-TB Gold test in detecting Mycobacterium tuberculosis infection in immunocompromised patients. Eur J Int Med 2008;19:137-9.
41. Ulrichs T, Munk ME, Mollenkopf H et al. Diferential T cell responses to Mycobacterium tuberculosis ESAT6 in tuberculosis patients and healthy donors. Eur J Immunol 1998;28:3949-58.
42. Van Pinxteren LA, Ravn P, Agger EM et al. Diagnosis of tuberculosis based on the two specific antigens ESAT-6 and CFP-10. Clin Diagn Lab Immun 2000;7:155-60.
43. Vilaplana C, Ruiz-Manzano J, Gil O et al. The tuberculin skin test increases the responses measured by T cell interferon-gamma release assays. Scan J immunol 2008;67:610-7.
44. Choi JC, Shin JW, Kim JY et al. The effect of previous tuberculin skin test on the follow-up examination of whole-blood interferon-gamma assay in the screening for the latent tuberculosis infection. Chest 2008;133:1415-20.
45. Leyten EMS, Prins C, Bosink AWJ et al. Efect of tuberculin skin testing on a Mycobacterium tuberculosis-specifc interferon- ã assay. Eur Respir J 2007;29:1212-6.
46. American Thoracic Society. Targeted tuberculin testing and treatment of latent TB infection. Am J Resp Crit Care 2000;161:221-47.
47. Hamilton C. TB in the cytokine era: what the rheumatologists need to know. Arth Rheum 2003;48:2085-91.
48. Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V et al. Efectiveness of recommendations to prevent reactivation of latent TB infection in patients treated with tumor necrosis factor antagonists. Arth Rheum 2005;52:1766-72.
49. Zabana Y, Domènech E, San Roman AL et al. Tuberculous chemoprophy-laxis requirements and safety in inflammatory bowel disease patients prior to anti-TNF therapy. Inflamm Bowel Dis 2008;14:1387-91.
50. Alter MJ. Epidemiology of hepatitis B in Europe and in worldwide. J Hepatol 2003;39 (Suppl I):S64-9.
51. Lalazar G, Rund D, Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol 2007;136:699-712.
52. Yeo W Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006;43:209-20.
53. Calabrese LH, Zein NN, Vassilopoulos D. Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. Ann Rheum Dis 2006;65:983-9.
54. Guidotti LG, Chisari FV. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol 2001;19:65-91.
55. Herbein G, O'Brien WA. Tumor necrosis factor (TNF)-alpha and TNF receptors in viral pathogenesis. Proc Soc Exp Biol Med 2000;223:241-57.
56. Kasahara S, Ando K, Saito K et al. Lack of tumor necrosis factor alpha induces impaired proliferation of hepatitis B virus-specific cytotoxic T lymphocytes. J Virol 2003;77:2469-76.
57. Oniankitan O, Duvoux C, Challine D et al. Infiximab therapy for rheumatic disease in patients with chronic hepatitis B or C. J Rheumatol 2004;31:107-9.
58. Anelli MG, Torres DD Manno C et al. Improvement of renal function and disappearance of hepatitis B virus DNA in a patient with rheumatoid arthritis and renal amyloidosis following treatment with infliximab. Arth Rheum 2005;52:2519-20.
59. Ostuni P , Botsios C, Punzi L et al. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose of methotrexate. Ann Rheum Dis 2003;62:686-7.
60. Wendling D, Auge B, Bettinger D et al. Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy. Ann Rheum Dis 2005;64:788-9.
61. Michel M, Duvoux C, Hezode C et al. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for adult onset Still's disease. J Rheumatol 2003;30:1624-5.
62. Ueno Y, Tanaka S, Shimamoto M et al. Infiximab therapy for Crohn's disease in a patient with chronic hepatitis B. Digest Dis Sci 2005;50:163-6.
63. Esteve M, Saro C, Gonzalez-Huix F et al. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 2004;53:1363-5.
64. Calabrese LH, Zein N, Vassilopoulos D. Safety of antitumor necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Ann Rheum Dis 2004;63:18-24.
65. Del Valle Garcia-Sanchez M, Gomez-Camacho F, Poyato-Gonzalez A et al. Infiximab therapy in a patient with Crohn's disease and chronic hepatitis virus infection. Inflamm Bowel Dis 2004;10:701-2.
66. Roux CH, Brocq O, Breuil V et al. Safety of anti-TNF-α therapy in rheumatoid arthritis and spondyloarthropathies with concurrent B or C chronic hepatitis. Rheumatology 2006;45:1294-7.
67. Carroll MB, Bond IB. Use of tumor necrosis factor-α inhibitors in patients with chronic hepatitis B infection. Semin Arthritis Rheum 2008;38:208-17.
68. Lavanchy D, McMahon B. Worldwide prevalence and prevention of hepatitis C. In: Liang TJ, Hoofnagle JH (eds). Hepatitis C. Academic Press: San Diego , 2000 pp. 186-201.
69. Chuang E, Del Vecchio A, Smolinski S et al. Biomedicines to reduce inflammation but not viral load in chronic HCV: what's the sense? Trends Biotechnol 2004;22:517-23.
70. Freeman AJ, Marinos G, French RA et al. Immunopathogenesis of hepatitis C virus infection. Immunol Cell Biol 2001;79515-36.
71. Zuckerman E, Zuckerman T, Douer D et al. Liver dysfunction in patients infected with hepatitis C virus undergoing chemotherapy for hematologic malignancies. Cancer 1998;83:1224-30.
72. Faggioli P, De Paschale M, Tocci A et al. Acute hepatic toxicity during cyclic chemotherapy in non Hodgkin's lymphoma. Haematology 1997;82:38-42.
73. Parke FA, Reveille JD. Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection. Arthr Rheum 2004;51:800-4.
74. Holtmann MH, Galle PR, Neurath MF. Treatment of patients with Crohn's disease and concomitant chronic hepatitis C with a chimeric monoclonal antibody to TNF. Am J Gastroenterol 2003;98:504-5.
75. Campbell S, Ghosh S. Infiximab therapy for Crohn's disease in the presence of chronic hepatitis C infection. Eur J Gastroenterol Hepatol 2001;13:191-2.
76. Magliocco MA, Gottlieb AB. Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis virus C infection: report of 3 cases. J Am Acad Dermatol 2004;51:580-4.
77. Khanna M, Shirodkar MA, Gottlieb AB. Etanercept therapy in patients with autoimmunity and hepatitis C. J Dermatolog Treat 2003;14:229-32.
78. Peterson JR, HSU FC, Simkin PA et al. Efect of tumor necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis 2003;62:1078-82.
79. Chandesris MO, Gayet S, Schleinitz N et al. Infiximab in the treatment of refractory vasculitis secondary to hepatitis C-associated mixed cryoglobuli-naemia. Rheumatology 2005;43:532-3.
80. Zeinn NN et al. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol 2005;42:315-22.
81. Ferri C, Ferraccioli G, Ferrari D et al. Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection. J Rheumatol 2008;35:1944-9.
82. Marzano A, Angelucci E, Andreone P et al. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liv Dis 2007;39:397-408.
83. Nathan DM, Angus WA, Gibson PR. Hepatitis B and C virus infections and anti-tumor necrosis factor-a therapy: guidelines for clinical approach. J Gastroen Hepatol 2006;21:1366-71.
84. Madonia S, Orlando A, Scimeca D et al. Occult hepatitis B and infliximab-induced HBV reactivation. Inflamm Bowel Dis 2007;13:508-9.
85. Tartakovsky B, Ben-Yair E. Cytokines modulate preimplantation development and pregnancy. DevBiol 1991;146:343-52.
86. Yu XW, Yan CF, Jin HL, Li X. Tumor necrosis factor receptor 1 expression and early spontaneous abortion. Int J Gynecol Obstet 2005;88:44-8.
87. Munkholm P. Crohn's disease - occurrence, course and prognosis. An epidemiological cohort study. Dan Med Bull 1997;44:287-302.
88. Baiocco PJ, Korelitz BI. The influence of inflammatory bowel disease and its treatment on pregnancy and foetal outcome. J Clin Gastroenterol 1984;6:211-6.
89. Cornish J, Tan E, Teare J et al. A meta-analysis on the influence of inflammatory bowel disease of pregnancy. Gut 2007;56:830-7.
90. Dominitz JA, Young JC, Boyko EJ et al. Outcomes of infants born to mothers with inflammatory bowel disease: a population based cohort study. Am J Gastroenterol 2001;96:635-43.
91. Norgard B, Hundborg HH, Jacobsen BA et al. Disease activity in pregnant women with Crohn's disease and birth outcomes: a Regional Danish Cohort study. Am J Gastroenterol 2007;102:1947-54.
92. ODonnell S, OMorain C. Review article: use of antitumor necrosis factor therapy in inflammatory bowel disease during pregnancy and conception. Aliment Pharmacol Ther 2008;27:885-94.
93. Mahadevan U Fertility and pregnancy in the patient with inflammatory bowel disease. Gut 2006;55:1198-206.
94. Dubinsky M, Abraham B, Mahadevan U Management of the pregnant IBD patient. Inflamm Bowel 2008;14:1736-50.
95. Mahadevan U, Sandborn WJ, Li D-K et al. Pregnancy outcomes in women with inflammatory bowel disease: a large community-based study from Northern California. Gastroenterology 2007;133:1106-12.
96. Lichtenstein G, Cohen RD, Feagan BG et al. Safety of infiximab in Crohn's disease: data from the 5000-patients TREAT registry. Gastroenterology 2004;126:A54.
97. Katz JA, Antoni C, Keenan GF et al. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol 2004;99:2385-92.
98. Srinivasan R. Infiximab treatment and pregnancy outcome in active Crohn's disease. Am J Gastroenterol 2001;96:2274-5.
99. James RL, Pearson LL. Successful treatment of pregnancy-triggered Crohn's disease complicated by severe recurrent life-threatening gastrointestinal bleeding. Am J Gastroenterol 2001;96:S295.
100. Bank LHB. Unexpected dramatic clinical response of psoriasis lesions and unexpected pregnancy in a infertile patient in response to treatment with anti-tumor necrosis factor monoclonal antibody for Crohn's disease. Am J Gastroenterol 2002;97:S260.
101. Burt MJ, Frizelle FA, Barbezat GO. Pregnancy and exposure to infliximab (anti-tumor necrosis factor-alpha monoclonal antibody). J Gastroent Hepatol 2003;18:465-6.
102. Joven BE, Garcia-Gonzales AJ, Ruiz T et al. Pregnancy in women receiving anti TNF therapy. Experience in Spain. Arthritis Rheum 2005;52:S349.
103. Kinder AJ, Edwards J, Samanta A et al. Pregnancy in a rheumatoid arthritis patient on infliximab and methotrexate. Rheumatology (Oxford) 2004;43:1195-6.
104. Roux CH, Brocq O, Breuil V Albert C, Euller-Ziegler L. Pregnancy in rheumatology patients exposed to anti-tumor necrosis factor (TNF)-α therapy. Rheumatology 2007;46:695-8.
105. Stengel JZ, Arnold HL. Is infliximab safe to use while breastfeeding? World J Gastroenterol 2008;14:3085-7.
106. Mahadevan U, Kane S, Sandborn WJ et al. Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease. Aliment Pharm Therap 2005;21:733-8.
107. Tursi A. Efect of intentional infliximab use throughout pregnancy in inducing and maintaining remission in Crohn's disease. Dig Liver Dis 2006;38:437-40.
108. Vasiliauskas EA, Church JA, Si lverman N et al. Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin Gastroenterol Hepatol 2006;4:1255-8.
109. Mahadevan U, Terdiman JP, Church J et al. Infiximab levels in infants born to women with inflammatory bowel disease. Gastroenterology 2007 ; 132 (Suppl 1): A-144:959.
110. Mahadevan U, Kane SV, Church JA et al. The effect of maternal peri-partum infliximab use on neonatal immune response. Gastroenterology 2008 ; 134 (Suppl.1): A-69:499.
111. Biancone L, Calabrese E, Petruzziello C et al. Treatment with biologic therapies and the risk of cancer in patients with IBD. Nat Clin Pract Gastroenterol Hepatol 2007;4:78-91.
112. Peyrin-Biroulet L, Deltenre P, De Suray N et al. Effcacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008;6:644-53.
113. Biancone L, Orlando A, Kohn A et al. Infiximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study. Gut 2006;55:228-33.
114. Periodic Safety Update Report (PSUR) 16: Infliximab; p. 97, Table 39. October 2007.
115. Periodic Safety Update Report (PSUR) 16: Infliximab; p. 108, Table 41. October 2007.
116. Siegel CA, Marden SM, Persing SM et al. Risk of lymphoma associated with anti-TNF agents for the treatment of Crohn's disease: a meta-analysis. Gastroenterology 2008;134 (Suppl.1): A144.
117. Rosh JR, Gross T, Mamula P et al. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale? Infamm Bowel Dis 2007;13:1024-30.
118. Shale M, Kanfer E, Panaccione R et al. Hepatosplenic T cell lymphoma in inflammatory bowel disease. Gut 2008;57:1639-41.
119. Balkwill F. TNF-alpha in promotion and progression of cancer. Cancer Metastasis Rev 2006;25:409-16.
120. Williams GM. Antitumor necrosis factor-α therapy and potential cancer inhibition. Eur J Cancer Prev 2008;17:169-77.
121. Harrison ML, Obermueller E, Maisey NR et al. Tumor necrosis factor α as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose. J Clin Oncol 2007;25:4542-9.
122. Egberts JH, Cloosters V, Noack A et al. Anti-tumor necrosis factor therapy inhibits pancreatic tumor growth and metastasis. Cancer Res 2008;68:1443-50.
123. Kane S, Khatibi B, Ready D. Higher incidence of abnormal Pap smears in women with inflammatory bowel disease. Am J Gastroenterol 2008;103:631-6.
124. Antoniou C, Kosmadaki MG, Stratigos AJ et al. Genital HPV lesions and molluscum contagiosum occurring in patients receiving anti-TNF-α therapy. Dermatology 2008;216:364-5.